APO Research
Talk to an analyst

APO RESEARCH · REPORT

NK1 Receptor Antagonist

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global NK1 Receptor Antagonist Market Analysis and Forecast 2026-2032

23 December 2025199 pages

Choose your research edition.

Industry ResearchNK1 Receptor Antagonist Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal NK1 Receptor Antagonist Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal NK1 Receptor Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NK1 Receptor Antagonist Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal NK1 Receptor Antagonist Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global NK1 Receptor Antagonist market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for NK1 Receptor Antagonist is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for NK1 Receptor Antagonist is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for NK1 Receptor Antagonist is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for NK1 Receptor Antagonist is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of NK1 Receptor Antagonist include Glenmark, Heron Therapeutics, TerSera Therapeutics, Torrent Pharmaceuticals, Beijing Sihuan Pharmaceutical, Fresenius Kabi, Hansoh Pharma, Helsinn Healthcare and Jiangsu Hengrui Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for NK1 Receptor Antagonist, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of NK1 Receptor Antagonist, also provides the revenue of main regions and countries. Of the upcoming market potential for NK1 Receptor Antagonist, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the NK1 Receptor Antagonist revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global NK1 Receptor Antagonist market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for NK1 Receptor Antagonist revenue, projected growth trends, production technology, application and end-user industry.

NK1 Receptor Antagonist Segment by Company

Glenmark

Heron Therapeutics

TerSera Therapeutics

Torrent Pharmaceuticals

Beijing Sihuan Pharmaceutical

Fresenius Kabi

Hansoh Pharma

Helsinn Healthcare

Jiangsu Hengrui Pharmaceuticals

Luoxin Pharmaceutical

Merck

Qilu Pharmaceutical

Yichang Humanwell Pharmaceutical

Chia Tai Tianqing Pharmaceutical

NK1 Receptor Antagonist Segment by Type

Netupitant

Maropitant

Rolapitant

Fosaprepitant

Aprepitant

Other

NK1 Receptor Antagonist Segment by Application

Hospital

Specialty Clinic

NK1 Receptor Antagonist Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK1 Receptor Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NK1 Receptor Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK1 Receptor Antagonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of NK1 Receptor Antagonist in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of NK1 Receptor Antagonist company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, NK1 Receptor Antagonist revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global NK1 Receptor Antagonist Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Netupitant Major Player Table 3. Maropitant Major Player Table 4. Rolapitant Major Player Table 5. Fosaprepitant Major Player Table 6. Aprepitant Major Player Table 7. Other Major Player Table 8. Global NK1 Receptor Antagonist Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Hospital Major Player Table 10. Specialty Clinic Major Player Table 11. NK1 Receptor Antagonist Industry Trends Table 12. NK1 Receptor Antagonist Industry Drivers Table 13. NK1 Receptor Antagonist Industry Opportunities and Challenges Table 14. NK1 Receptor Antagonist Industry Restraints Table 15. Global NK1 Receptor Antagonist Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global NK1 Receptor Antagonist Market Size by Region (2021-2026) & (US$ Million) Table 17. Global NK1 Receptor Antagonist Market Share by Region (2021-2026) Table 18. Global NK1 Receptor Antagonist Market Size by Region (2027-2032) & (US$ Million) Table 19. Global NK1 Receptor Antagonist Market Share by Region (2027-2032) Table 20. Global NK1 Receptor Antagonist Revenue by Players (US$ Million) & (2021-2026) Table 21. Global NK1 Receptor Antagonist Revenue Market Share by Players (2021-2026) Table 22. Global NK1 Receptor Antagonist Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global NK1 Receptor Antagonist Key Players Headquarters & Area Served Table 24. Global NK1 Receptor Antagonist Players, Product Type & Application Table 25. Global NK1 Receptor Antagonist Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global NK1 Receptor Antagonist by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global NK1 Receptor Antagonist Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global NK1 Receptor Antagonist Revenue by Type (2021-2026) & (US$ Million) Table 30. Global NK1 Receptor Antagonist Revenue by Type (2027-2032) & (US$ Million) Table 31. Global NK1 Receptor Antagonist Revenue Market Share by Type (2021-2026) Table 32. Global NK1 Receptor Antagonist Revenue Market Share by Type (2027-2032) Table 33. Global NK1 Receptor Antagonist Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global NK1 Receptor Antagonist Revenue by Application (2021-2026) & (US$ Million) Table 35. Global NK1 Receptor Antagonist Revenue by Application (2027-2032) & (US$ Million) Table 36. Global NK1 Receptor Antagonist Revenue Market Share by Application (2021-2026) Table 37. Global NK1 Receptor Antagonist Revenue Market Share by Application (2027-2032) Table 38. Glenmark Company Information Table 39. Glenmark Business Overview Table 40. Glenmark NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Glenmark NK1 Receptor Antagonist Product Portfolio Table 42. Glenmark Recent Development Table 43. Heron Therapeutics Company Information Table 44. Heron Therapeutics Business Overview Table 45. Heron Therapeutics NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Heron Therapeutics NK1 Receptor Antagonist Product Portfolio Table 47. Heron Therapeutics Recent Development Table 48. TerSera Therapeutics Company Information Table 49. TerSera Therapeutics Business Overview Table 50. TerSera Therapeutics NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. TerSera Therapeutics NK1 Receptor Antagonist Product Portfolio Table 52. TerSera Therapeutics Recent Development Table 53. Torrent Pharmaceuticals Company Information Table 54. Torrent Pharmaceuticals Business Overview Table 55. Torrent Pharmaceuticals NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Torrent Pharmaceuticals NK1 Receptor Antagonist Product Portfolio Table 57. Torrent Pharmaceuticals Recent Development Table 58. Beijing Sihuan Pharmaceutical Company Information Table 59. Beijing Sihuan Pharmaceutical Business Overview Table 60. Beijing Sihuan Pharmaceutical NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Beijing Sihuan Pharmaceutical NK1 Receptor Antagonist Product Portfolio Table 62. Beijing Sihuan Pharmaceutical Recent Development Table 63. Fresenius Kabi Company Information Table 64. Fresenius Kabi Business Overview Table 65. Fresenius Kabi NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Fresenius Kabi NK1 Receptor Antagonist Product Portfolio Table 67. Fresenius Kabi Recent Development Table 68. Hansoh Pharma Company Information Table 69. Hansoh Pharma Business Overview Table 70. Hansoh Pharma NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Hansoh Pharma NK1 Receptor Antagonist Product Portfolio Table 72. Hansoh Pharma Recent Development Table 73. Helsinn Healthcare Company Information Table 74. Helsinn Healthcare Business Overview Table 75. Helsinn Healthcare NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Helsinn Healthcare NK1 Receptor Antagonist Product Portfolio Table 77. Helsinn Healthcare Recent Development Table 78. Jiangsu Hengrui Pharmaceuticals Company Information Table 79. Jiangsu Hengrui Pharmaceuticals Business Overview Table 80. Jiangsu Hengrui Pharmaceuticals NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Jiangsu Hengrui Pharmaceuticals NK1 Receptor Antagonist Product Portfolio Table 82. Jiangsu Hengrui Pharmaceuticals Recent Development Table 83. Luoxin Pharmaceutical Company Information Table 84. Luoxin Pharmaceutical Business Overview Table 85. Luoxin Pharmaceutical NK1 Receptor Antagonist Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Luoxin Pharmaceutical NK1 Receptor Antagonist Product Portfolio Table 87. Luoxin Pharmaceutical Recent Development Table 88. Merck Company Information Table 89. Merck Business Overview Table 90. Merck NK1 Receptor Antagonist Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Merck NK1 Receptor Antagonist Product Portfolio Table 92. Merck Recent Development Table 93. Qilu Pharmaceutical Company Information Table 94. Qilu Pharmaceutical Business Overview Table 95. Qilu Pharmaceutical NK1 Receptor Antagonist Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Qilu Pharmaceutical NK1 Receptor Antagonist Product Portfolio Table 97. Qilu Pharmaceutical Recent Development Table 98. Yichang Humanwell Pharmaceutical Company Information Table 99. Yichang Humanwell Pharmaceutical Business Overview Table 100. Yichang Humanwell Pharmaceutical NK1 Receptor Antagonist Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Yichang Humanwell Pharmaceutical NK1 Receptor Antagonist Product Portfolio Table 102. Yichang Humanwell Pharmaceutical Recent Development Table 103. Chia Tai Tianqing Pharmaceutical Company Information Table 104. Chia Tai Tianqing Pharmaceutical Business Overview Table 105. Chia Tai Tianqing Pharmaceutical NK1 Receptor Antagonist Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Chia Tai Tianqing Pharmaceutical NK1 Receptor Antagonist Product Portfolio Table 107. Chia Tai Tianqing Pharmaceutical Recent Development Table 108. North America NK1 Receptor Antagonist Revenue by Type (2021-2026) & (US$ Million) Table 109. North America NK1 Receptor Antagonist Revenue by Type (2027-2032) & (US$ Million) Table 110. North America NK1 Receptor Antagonist Revenue by Application (2021-2026) & (US$ Million) Table 111. North America NK1 Receptor Antagonist Revenue by Application (2027-2032) & (US$ Million) Table 112. North America NK1 Receptor Antagonist Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. North America NK1 Receptor Antagonist Revenue by Country (2021-2026) & (US$ Million) Table 114. North America NK1 Receptor Antagonist Revenue by Country (US$ Million) & (2027-2032) Table 115. Europe NK1 Receptor Antagonist Revenue by Type (2021-2026) & (US$ Million) Table 116. Europe NK1 Receptor Antagonist Revenue by Type (2027-2032) & (US$ Million) Table 117. Europe NK1 Receptor Antagonist Revenue by Application (2021-2026) & (US$ Million) Table 118. Europe NK1 Receptor Antagonist Revenue by Application (2027-2032) & (US$ Million) Table 119. Europe NK1 Receptor Antagonist Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. Europe NK1 Receptor Antagonist Revenue by Country (2021-2026) & (US$ Million) Table 121. Europe NK1 Receptor Antagonist Revenue by Country (US$ Million) & (2027-2032) Table 122. China NK1 Receptor Antagonist Revenue by Type (2021-2026) & (US$ Million) Table 123. China NK1 Receptor Antagonist Revenue by Type (2027-2032) & (US$ Million) Table 124. China NK1 Receptor Antagonist Revenue by Application (2021-2026) & (US$ Million) Table 125. China NK1 Receptor Antagonist Revenue by Application (2027-2032) & (US$ Million) Table 126. Asia NK1 Receptor Antagonist Revenue by Type (2021-2026) & (US$ Million) Table 127. Asia NK1 Receptor Antagonist Revenue by Type (2027-2032) & (US$ Million) Table 128. Asia NK1 Receptor Antagonist Revenue by Application (2021-2026) & (US$ Million) Table 129. Asia NK1 Receptor Antagonist Revenue by Application (2027-2032) & (US$ Million) Table 130. Asia NK1 Receptor Antagonist Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 131. Asia NK1 Receptor Antagonist Revenue by Region (US$ Million) & (2021-2026) Table 132. Asia NK1 Receptor Antagonist Revenue by Region (US$ Million) & (2027-2032) Table 133. SAMEA NK1 Receptor Antagonist Revenue by Type (2021-2026) & (US$ Million) Table 134. SAMEA NK1 Receptor Antagonist Revenue by Type (2027-2032) & (US$ Million) Table 135. SAMEA NK1 Receptor Antagonist Revenue by Application (2021-2026) & (US$ Million) Table 136. SAMEA NK1 Receptor Antagonist Revenue by Application (2027-2032) & (US$ Million) Table 137. SAMEA NK1 Receptor Antagonist Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 138. SAMEA NK1 Receptor Antagonist Revenue by Country (2021-2026) & (US$ Million) Table 139. SAMEA NK1 Receptor Antagonist Revenue by Country (US$ Million) & (2027-2032) Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. NK1 Receptor Antagonist Image Figure 2. Global NK1 Receptor Antagonist Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NK1 Receptor Antagonist Market Size Share 2021 VS 2025 VS 2032 Figure 4. Netupitant Image Figure 5. Maropitant Image Figure 6. Rolapitant Image Figure 7. Fosaprepitant Image Figure 8. Aprepitant Image Figure 9. Other Image Figure 10. Global NK1 Receptor Antagonist Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global NK1 Receptor Antagonist Market Size Share 2021 VS 2025 VS 2032 Figure 12. Hospital Image Figure 13. Specialty Clinic Image Figure 14. Global NK1 Receptor Antagonist Market Size (US$ Million) & (2021-2032) Figure 15. Global NK1 Receptor Antagonist Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global NK1 Receptor Antagonist Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global NK1 Receptor Antagonist Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global NK1 Receptor Antagonist Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global NK1 Receptor Antagonist Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global NK1 Receptor Antagonist Revenue Market Share by Type (2021-2032) Figure 22. Global NK1 Receptor Antagonist Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global NK1 Receptor Antagonist Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global NK1 Receptor Antagonist Revenue Market Share by Application (2021-2032) Figure 25. North America NK1 Receptor Antagonist Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America NK1 Receptor Antagonist Revenue Share by Type (2021-2032) Figure 27. North America NK1 Receptor Antagonist Revenue Share by Application (2021-2032) Figure 28. North America NK1 Receptor Antagonist Revenue Share by Country (2021-2032) Figure 29. United States NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe NK1 Receptor Antagonist Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe NK1 Receptor Antagonist Revenue Share by Type (2021-2032) Figure 34. Europe NK1 Receptor Antagonist Revenue Share by Application (2021-2032) Figure 35. Europe NK1 Receptor Antagonist Revenue Share by Country (2021-2032) Figure 36. Germany NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China NK1 Receptor Antagonist Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China NK1 Receptor Antagonist Revenue Share by Type (2021-2032) Figure 46. China NK1 Receptor Antagonist Revenue Share by Application (2021-2032) Figure 47. Asia NK1 Receptor Antagonist Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia NK1 Receptor Antagonist Revenue Share by Type (2021-2032) Figure 49. Asia NK1 Receptor Antagonist Revenue Share by Application (2021-2032) Figure 50. Asia NK1 Receptor Antagonist Revenue Share by Region (2021-2032) Figure 51. Japan NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA NK1 Receptor Antagonist Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA NK1 Receptor Antagonist Revenue Share by Type (2021-2032) Figure 59. SAMEA NK1 Receptor Antagonist Revenue Share by Application (2021-2032) Figure 60. SAMEA NK1 Receptor Antagonist Revenue Share by Country (2021-2032) Figure 61. Brazil NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt NK1 Receptor Antagonist Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Netupitant
  • Maropitant
  • Rolapitant
  • Fosaprepitant
  • Aprepitant
  • Other
Applications
  • Hospital
  • Specialty Clinic
Companies covered
  • Glenmark
  • Heron Therapeutics
  • TerSera Therapeutics
  • Torrent Pharmaceuticals
  • Beijing Sihuan Pharmaceutical
  • Fresenius Kabi
  • Hansoh Pharma
  • Helsinn Healthcare
  • Jiangsu Hengrui Pharmaceuticals
  • Luoxin Pharmaceutical
  • Merck
  • Qilu Pharmaceutical
  • Yichang Humanwell Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 NK1 Receptor Antagonist Market by Type
  3. 1.2.1 Global NK1 Receptor Antagonist Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Netupitant
  5. 1.2.3 Maropitant
  6. 1.2.4 Rolapitant
  7. 1.2.5 Fosaprepitant
  8. 1.2.6 Aprepitant
  9. 1.2.7 Other
  10. 1.3 NK1 Receptor Antagonist Market by Application
  11. 1.3.1 Global NK1 Receptor Antagonist Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Hospital
  13. 1.3.3 Specialty Clinic
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 NK1 Receptor Antagonist Market Dynamics
  1. 2.1 NK1 Receptor Antagonist Industry Trends
  2. 2.2 NK1 Receptor Antagonist Industry Drivers
  3. 2.3 NK1 Receptor Antagonist Industry Opportunities and Challenges
  4. 2.4 NK1 Receptor Antagonist Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global NK1 Receptor Antagonist Market Perspective (2021-2032)
  2. 3.2 Global NK1 Receptor Antagonist Growth Trends by Region
  3. 3.2.1 Global NK1 Receptor Antagonist Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global NK1 Receptor Antagonist Market Size by Region (2021-2026)
  5. 3.2.3 Global NK1 Receptor Antagonist Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global NK1 Receptor Antagonist Revenue by Players
  2. 4.1.1 Global NK1 Receptor Antagonist Revenue by Players (2021-2026)
  3. 4.1.2 Global NK1 Receptor Antagonist Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global NK1 Receptor Antagonist Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global NK1 Receptor Antagonist Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global NK1 Receptor Antagonist Key Players Headquarters & Area Served
  7. 4.4 Global NK1 Receptor Antagonist Players, Product Type & Application
  8. 4.5 Global NK1 Receptor Antagonist Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global NK1 Receptor Antagonist Market CR5 and HHI
  11. 4.6.3 2025 NK1 Receptor Antagonist Tier 1, Tier 2, and Tier 3
5 NK1 Receptor Antagonist Market Size by Type
  1. 5.1 Global NK1 Receptor Antagonist Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global NK1 Receptor Antagonist Revenue by Type (2021-2032)
  3. 5.3 Global NK1 Receptor Antagonist Revenue Market Share by Type (2021-2032)
6 NK1 Receptor Antagonist Market Size by Application
  1. 6.1 Global NK1 Receptor Antagonist Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global NK1 Receptor Antagonist Revenue by Application (2021-2032)
  3. 6.3 Global NK1 Receptor Antagonist Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Glenmark
  2. 7.1.1 Glenmark Company Information
  3. 7.1.2 Glenmark Business Overview
  4. 7.1.3 Glenmark NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Glenmark NK1 Receptor Antagonist Product Portfolio
  6. 7.1.5 Glenmark Recent Developments
  7. 7.2 Heron Therapeutics
  8. 7.2.1 Heron Therapeutics Company Information
  9. 7.2.2 Heron Therapeutics Business Overview
  10. 7.2.3 Heron Therapeutics NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Heron Therapeutics NK1 Receptor Antagonist Product Portfolio
  12. 7.2.5 Heron Therapeutics Recent Developments
  13. 7.3 TerSera Therapeutics
  14. 7.3.1 TerSera Therapeutics Company Information
  15. 7.3.2 TerSera Therapeutics Business Overview
  16. 7.3.3 TerSera Therapeutics NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  17. 7.3.4 TerSera Therapeutics NK1 Receptor Antagonist Product Portfolio
  18. 7.3.5 TerSera Therapeutics Recent Developments
  19. 7.4 Torrent Pharmaceuticals
  20. 7.4.1 Torrent Pharmaceuticals Company Information
  21. 7.4.2 Torrent Pharmaceuticals Business Overview
  22. 7.4.3 Torrent Pharmaceuticals NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Torrent Pharmaceuticals NK1 Receptor Antagonist Product Portfolio
  24. 7.4.5 Torrent Pharmaceuticals Recent Developments
  25. 7.5 Beijing Sihuan Pharmaceutical
  26. 7.5.1 Beijing Sihuan Pharmaceutical Company Information
  27. 7.5.2 Beijing Sihuan Pharmaceutical Business Overview
  28. 7.5.3 Beijing Sihuan Pharmaceutical NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Beijing Sihuan Pharmaceutical NK1 Receptor Antagonist Product Portfolio
  30. 7.5.5 Beijing Sihuan Pharmaceutical Recent Developments
  31. 7.6 Fresenius Kabi
  32. 7.6.1 Fresenius Kabi Company Information
  33. 7.6.2 Fresenius Kabi Business Overview
  34. 7.6.3 Fresenius Kabi NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Fresenius Kabi NK1 Receptor Antagonist Product Portfolio
  36. 7.6.5 Fresenius Kabi Recent Developments
  37. 7.7 Hansoh Pharma
  38. 7.7.1 Hansoh Pharma Company Information
  39. 7.7.2 Hansoh Pharma Business Overview
  40. 7.7.3 Hansoh Pharma NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Hansoh Pharma NK1 Receptor Antagonist Product Portfolio
  42. 7.7.5 Hansoh Pharma Recent Developments
  43. 7.8 Helsinn Healthcare
  44. 7.8.1 Helsinn Healthcare Company Information
  45. 7.8.2 Helsinn Healthcare Business Overview
  46. 7.8.3 Helsinn Healthcare NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Helsinn Healthcare NK1 Receptor Antagonist Product Portfolio
  48. 7.8.5 Helsinn Healthcare Recent Developments
  49. 7.9 Jiangsu Hengrui Pharmaceuticals
  50. 7.9.1 Jiangsu Hengrui Pharmaceuticals Company Information
  51. 7.9.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  52. 7.9.3 Jiangsu Hengrui Pharmaceuticals NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Jiangsu Hengrui Pharmaceuticals NK1 Receptor Antagonist Product Portfolio
  54. 7.9.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  55. 7.10 Luoxin Pharmaceutical
  56. 7.10.1 Luoxin Pharmaceutical Company Information
  57. 7.10.2 Luoxin Pharmaceutical Business Overview
  58. 7.10.3 Luoxin Pharmaceutical NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Luoxin Pharmaceutical NK1 Receptor Antagonist Product Portfolio
  60. 7.10.5 Luoxin Pharmaceutical Recent Developments
  61. 7.11 Merck
  62. 7.11.1 Merck Company Information
  63. 7.11.2 Merck Business Overview
  64. 7.11.3 Merck NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Merck NK1 Receptor Antagonist Product Portfolio
  66. 7.11.5 Merck Recent Developments
  67. 7.12 Qilu Pharmaceutical
  68. 7.12.1 Qilu Pharmaceutical Company Information
  69. 7.12.2 Qilu Pharmaceutical Business Overview
  70. 7.12.3 Qilu Pharmaceutical NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Qilu Pharmaceutical NK1 Receptor Antagonist Product Portfolio
  72. 7.12.5 Qilu Pharmaceutical Recent Developments
  73. 7.13 Yichang Humanwell Pharmaceutical
  74. 7.13.1 Yichang Humanwell Pharmaceutical Company Information
  75. 7.13.2 Yichang Humanwell Pharmaceutical Business Overview
  76. 7.13.3 Yichang Humanwell Pharmaceutical NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Yichang Humanwell Pharmaceutical NK1 Receptor Antagonist Product Portfolio
  78. 7.13.5 Yichang Humanwell Pharmaceutical Recent Developments
  79. 7.14 Chia Tai Tianqing Pharmaceutical
  80. 7.14.1 Chia Tai Tianqing Pharmaceutical Company Information
  81. 7.14.2 Chia Tai Tianqing Pharmaceutical Business Overview
  82. 7.14.3 Chia Tai Tianqing Pharmaceutical NK1 Receptor Antagonist Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Chia Tai Tianqing Pharmaceutical NK1 Receptor Antagonist Product Portfolio
  84. 7.14.5 Chia Tai Tianqing Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America NK1 Receptor Antagonist Revenue (2021-2032)
  2. 8.2 North America NK1 Receptor Antagonist Revenue by Type (2021-2032)
  3. 8.2.1 North America NK1 Receptor Antagonist Revenue by Type (2021-2026)
  4. 8.2.2 North America NK1 Receptor Antagonist Revenue by Type (2027-2032)
  5. 8.3 North America NK1 Receptor Antagonist Revenue Share by Type (2021-2032)
  6. 8.4 North America NK1 Receptor Antagonist Revenue by Application (2021-2032)
  7. 8.4.1 North America NK1 Receptor Antagonist Revenue by Application (2021-2026)
  8. 8.4.2 North America NK1 Receptor Antagonist Revenue by Application (2027-2032)
  9. 8.5 North America NK1 Receptor Antagonist Revenue Share by Application (2021-2032)
  10. 8.6 North America NK1 Receptor Antagonist Revenue by Country
  11. 8.6.1 North America NK1 Receptor Antagonist Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America NK1 Receptor Antagonist Revenue by Country (2021-2026)
  13. 8.6.3 North America NK1 Receptor Antagonist Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe NK1 Receptor Antagonist Revenue (2021-2032)
  2. 9.2 Europe NK1 Receptor Antagonist Revenue by Type (2021-2032)
  3. 9.2.1 Europe NK1 Receptor Antagonist Revenue by Type (2021-2026)
  4. 9.2.2 Europe NK1 Receptor Antagonist Revenue by Type (2027-2032)
  5. 9.3 Europe NK1 Receptor Antagonist Revenue Share by Type (2021-2032)
  6. 9.4 Europe NK1 Receptor Antagonist Revenue by Application (2021-2032)
  7. 9.4.1 Europe NK1 Receptor Antagonist Revenue by Application (2021-2026)
  8. 9.4.2 Europe NK1 Receptor Antagonist Revenue by Application (2027-2032)
  9. 9.5 Europe NK1 Receptor Antagonist Revenue Share by Application (2021-2032)
  10. 9.6 Europe NK1 Receptor Antagonist Revenue by Country
  11. 9.6.1 Europe NK1 Receptor Antagonist Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe NK1 Receptor Antagonist Revenue by Country (2021-2026)
  13. 9.6.3 Europe NK1 Receptor Antagonist Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China NK1 Receptor Antagonist Revenue (2021-2032)
  2. 10.2 China NK1 Receptor Antagonist Revenue by Type (2021-2032)
  3. 10.2.1 China NK1 Receptor Antagonist Revenue by Type (2021-2026)
  4. 10.2.2 China NK1 Receptor Antagonist Revenue by Type (2027-2032)
  5. 10.3 China NK1 Receptor Antagonist Revenue Share by Type (2021-2032)
  6. 10.4 China NK1 Receptor Antagonist Revenue by Application (2021-2032)
  7. 10.4.1 China NK1 Receptor Antagonist Revenue by Application (2021-2026)
  8. 10.4.2 China NK1 Receptor Antagonist Revenue by Application (2027-2032)
  9. 10.5 China NK1 Receptor Antagonist Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia NK1 Receptor Antagonist Revenue (2021-2032)
  2. 11.2 Asia NK1 Receptor Antagonist Revenue by Type (2021-2032)
  3. 11.2.1 Asia NK1 Receptor Antagonist Revenue by Type (2021-2026)
  4. 11.2.2 Asia NK1 Receptor Antagonist Revenue by Type (2027-2032)
  5. 11.3 Asia NK1 Receptor Antagonist Revenue Share by Type (2021-2032)
  6. 11.4 Asia NK1 Receptor Antagonist Revenue by Application (2021-2032)
  7. 11.4.1 Asia NK1 Receptor Antagonist Revenue by Application (2021-2026)
  8. 11.4.2 Asia NK1 Receptor Antagonist Revenue by Application (2027-2032)
  9. 11.5 Asia NK1 Receptor Antagonist Revenue Share by Application (2021-2032)
  10. 11.6 Asia NK1 Receptor Antagonist Revenue by Country
  11. 11.6.1 Asia NK1 Receptor Antagonist Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia NK1 Receptor Antagonist Revenue by Country (2021-2026)
  13. 11.6.3 Asia NK1 Receptor Antagonist Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA NK1 Receptor Antagonist Revenue (2021-2032)
  2. 12.2 SAMEA NK1 Receptor Antagonist Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA NK1 Receptor Antagonist Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA NK1 Receptor Antagonist Revenue by Type (2027-2032)
  5. 12.3 SAMEA NK1 Receptor Antagonist Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA NK1 Receptor Antagonist Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA NK1 Receptor Antagonist Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA NK1 Receptor Antagonist Revenue by Application (2027-2032)
  9. 12.5 SAMEA NK1 Receptor Antagonist Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA NK1 Receptor Antagonist Revenue by Country
  11. 12.6.1 SAMEA NK1 Receptor Antagonist Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA NK1 Receptor Antagonist Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA NK1 Receptor Antagonist Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst